Worldcrunch on MSN3d
Lecanemab: Why This Could Be The Beginning Of The End Of Alzheimer’s
The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...
Hosted on MSN8h
Ozempic and Viagra, among the more than 80 drugs expected to work against Alzheimer's in the coming years
Today, the first monoclonal antibodies, lecanemab and donanemab, are available, showing that their reduction effect on these ...
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Biogen downgraded to Hold by Needham amid projected flat revenues until 2026. Leqembi and other new product sales show ...
News Medical on MSN13h
Finger-Prick Test Brings Alzheimer’s Detection Closer to Everyone
A new Alzheimer’s test collects just a few drops of blood from a finger prick, which can be mailed to a lab for analysis.
European committee takes a second look at Alzheimer's drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
DPA International on MSN4d
EU regulator reverses decision to block Alzheimer's drug lecanemab
The European Union's drugs regulator reversed its decision to block the Alzheimer's drug lecanemab, a treatment aimed at ...
Medscape3d
Leqembi Okayed for Subset of Early Alzheimer’s Patients
The European Medicines Agency re-examined clinical data of a subset of patients with one or no copies of the APOE4 gene ...
Medpage Today on MSN7d
Alzheimer's Data Withdrawn
A preprint research letter linking the Alzheimer's drug lecanemab (Leqembi) with excess deaths was withdrawn last week. The ...
Nasdaq4d
CHMP issues positive recommendation for approval of lecanemab in the EU
The CHMP recommendation for the European Commission to approve lecanemab follows Eisai's request for a re-examination of the CHMP's earlier negative recommendation. A decision from the European ...
Eisai receives positive CHMP opinion for Lecanemab in early Alzheimer’s disease
Eisai (ESAIY) and Biogen (BIIB) announced that a positive opinion has been received from the Committee for Medicinal Products for Human Use of ...
The Florida Times-Union6d
Alzheimer's is life-changing for 'everyone around them'; Jacksonville walkers show support
The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
1. About lecanemab (generic name, brand name: Leqembi®) Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal ...